Abbott Slaps Watson With Patent Suit Over Niaspan Generic

Law360, New York (November 9, 2012, 5:12 PM EST) -- Watson Pharmaceuticals Inc. was the latest generic drug maker to be hit with a patent suit over Abbott Laboratories unit AbbVie Inc.'s ongoing legal battle to shield its cholesterol drug Niaspan from generic competitors.

In a complaint filed in Delaware federal court, AbbVie claimed it filed its suit after Watson’s September abbreviated new drug application to the U.S. Food and Drug Administration to sell niacin tablets as generic versions of Niaspan, which it claimed would infringe two of its patents.

“Upon information and belief, Watson had...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.